Bionomics Limited, an Australian and US-based clinical-stage biopharmaceutical company, focuses on discovering and developing new drug candidates to address central nervous system disorders and certain types of cancer. Their key drug candidate, BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, recently finished its phase 2 clinical trial for treating social anxiety disorder and post-traumatic stress disorder. Additionally, the company is working on BNC375, a small molecule therapeutics to help alleviate cognitive impairment in Alzheimer's patients. Other drugs in the pipeline include BNC101, a monoclonal antibody that completed phase 1 clinical trials targeting cancer stem cells, and BNC105, a vascular disrupting agent currently in phase 2 clinical trials for refractory colorectal cancer and phase 1 clinical trials for relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. for one of their drugs. The company was founded in 1996 and is based in Eastwood, Australia.